Results 101 to 110 of about 38,007 (143)

Extended interval aminoglycoside dosing: from concept to clinic

International Journal of Antimicrobial Agents, 2002
Extended-interval aminoglycoside dosing (EIAD), while a relatively recent concept in mainstream clinical practice, actually has its roots in the mid 1970s. Early trial and error approaches of manipulating the dosage regimen to avoid toxicity and improve efficacy have helped to characterize the pharmacodynamic properties of these drugs.
David Nicolau, Dana Maglio, Charles H Nightingale   +2 more
exaly   +3 more sources

Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing

Multiple Sclerosis and Related Disorders, 2019
Natalizumab (NTZ) is a highly efficacious therapeutic for multiple sclerosis (MS), but treatment is associated with an increased risk of progressive multifocal leukoencephalopathy (PML). Extended interval dosing (EID) of NTZ has been proposed as an alternative dosing strategy to reduce PML risk. Pharmacokinetic (PK) and pharmacodynamic (PD) profiles of
John F, Foley, Susan, Goelz, Tamara, Hoyt, Angelene, Christensen, Ryan R, Metzger   +4 more
exaly   +3 more sources

Extended-interval Aminoglycoside Dosing in Pediatrics

Pediatric Infectious Disease Journal, 2011
Aminoglycosides (AGs) are often used in combination with -lactam antibiotics for the treatment of serious Gram-negative infections. Traditionally, AGs have been dosed multiple times a day. Over the past decade, extended-interval dosing has been evaluated as a method of improving the efficacy and safety of AGs.
Alice M, Jenh, Pranita D, Tamma, Aaron M, Milstone   +2 more
openaire   +2 more sources

Natalizumab extended-interval dosing in a real-life setting

Journal of the Neurological Sciences, 2023
Natalizumab is a high-efficacy therapy for recurrent multiple sclerosis (RMS) with a four-week administration interval. Controlled trials have shown that extending this interval to six weeks led to better safety without increasing the risk of relapse. We aimed to analyze the safety of extending the natalizumab interdose interval from 4 to 6 weeks in a ...
Lina, Jeantin, Marine, Boudot de la Motte, Romain, Deschamps, Antoine, Gueguen, Olivier, Gout, Augustin, Lecler, Caroline, Papeix, Caroline, Bensa   +7 more
openaire   +2 more sources

Feasibility of extended dosing intervals of denosumab

Journal of Oncology Pharmacy Practice, 2017
Purpose Denosumab is a crucial supportive care agent for patients with advanced cancers affecting the bone. Despite the importance of treatment, logistical and financial obstacles hinder the ability to maintain long-term adherence.
Jacob K, Kettle, Puja B, Patel
openaire   +2 more sources

Atorvastatin: Extended-Interval Dosing

Hospital Pharmacy, 2011
This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration.
Joyce A. Generali, Dennis J. Cada
openaire   +1 more source

Rosuvastatin: Extended-Interval Dosing

Hospital Pharmacy, 2011
This Hospital Pharmacy feature is extracted from Off-Label Drug Pacts, a quarterly publication available from Wolters Kluwer Health. Off-Label Drug Pacts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration.
A. Generali Joyce, J. Cada Dennis
openaire   +1 more source

National Survey of Extended-Interval Aminoglycoside Dosing

Clinical Infectious Diseases, 2000
A random sample survey of 500 acute care hospitals in the United States was conducted to evaluate the adoption of extended-interval aminoglycoside dosing (EIAD). The survey revealed that EIAD has been adopted in 3 of every 4 acute care hospitals, a 4-fold increase since 1993. Of the 74.7% of hospitals reporting EIAD, 64% had written guidelines.
S K, Chuck, S R, Raber, K A, Rodvold, D, Areff   +3 more
openaire   +2 more sources

Extended interval dosing of natalizumab in multiple sclerosis

Journal of Neurology, Neurosurgery & Psychiatry, 2016
Natalizumab (NTZ), a monoclonal antibody to human α4β1/β7 integrin, is an effective therapy for multiple sclerosis (MS), albeit associated with progressive multifocal leukoencephalopathy (PML). Clinicians have been extending the dose of infusions with a hypothesis of reducing PML risk.
L, Zhovtis Ryerson, T C, Frohman, J, Foley, I, Kister, B, Weinstock-Guttman, C, Tornatore, K, Pandey, S, Donnelly, S, Pawate, R, Bomprezzi, D, Smith, C, Kolb, S, Qureshi, D, Okuda, J, Kalina, Z, Rimler, R, Green, N, Monson, T, Hoyt, M, Bradshaw, J, Fallon, E, Chamot, M, Bucello, S, Beh, G, Cutter, E, Major, J, Herbert, E M, Frohman   +27 more
openaire   +2 more sources

Extended Interval Dosing of Gentamicin in Preterm Infants

American Journal of Perinatology, 2004
Conventional interval dosing (CID) and extended interval dosing (EID) of gentamicin were compared in preterm infants. Gentamicin peak and trough levels, serum creatinine, urine output, and hearing screens were obtained in 40 preterm infants. Results suggest that EID is safe, provides gentamicin levels in desirable ranges (peak, 5 to 12 microg/mL ...
Ma Cecilia K, Mercado, Nancy L, Brodsky, Michael K, McGuire, Hallam, Hurt   +3 more
openaire   +2 more sources